Presentation of Pancreatic Cancer Clinical Results at ASCO 2026
Latest Developments in Next-Generation KRAS Inhibitor Development

On July 15th, Yonsei Cancer Hospital announced that it held a special lecture titled "From Basic Science to Therapeutics: GRIT (Gastrointestinal Cancer RAS Innovative Therapeutic Development)" at the Seoham Auditorium of Yonsei Cancer Hospital in Seodaemun-gu, Seoul, inviting Professor Woongki Park from the Department of Medical Oncology at Memorial Sloan Kettering Cancer Center (MSKCC), who also serves as a visiting professor at the Department of Biomedical Science, Yonsei University College of Medicine.


The lecture covered the current progress on the development of KRAS inhibitors, which are emerging as a major target for pancreatic cancer treatment, as well as future therapeutic strategies. Based on research presented at the American Society of Clinical Oncology (ASCO 2026) Annual Meeting, the clinical significance and potential applications of KRAS-targeted therapies were also discussed.


On the 15th, Professor Woong-ki Park of the Memorial Sloan Kettering Cancer Center's Department of Medical Oncology is giving a special lecture at the Seoam Auditorium of Yonsei Cancer Hospital in Seodaemun-gu, Seoul. Severance Hospital

On the 15th, Professor Woong-ki Park of the Memorial Sloan Kettering Cancer Center's Department of Medical Oncology is giving a special lecture at the Seoam Auditorium of Yonsei Cancer Hospital in Seodaemun-gu, Seoul. Severance Hospital

View original image

Professor Park explained the background behind KRAS being long regarded as an "undruggable target," the research processes undertaken to overcome this challenge, and next-generation strategies designed to target various KRAS mutations.


He specifically introduced the Phase 3 clinical trial results of Daroctonrasib, which were presented at ASCO 2026. Daroctonrasib, a next-generation RAS inhibitor under development by Revolution Medicines in the United States, demonstrated approximately double the survival benefit compared with existing treatments for patients with metastatic pancreatic cancer who had previously received chemotherapy. The study results were also published in the international academic journal "The New England Journal of Medicine (NEJM)" during the same period.


In addition, Professor Park, who serves as the global principal investigator (Global PI), introduced recent developments in next-generation KRAS-targeted therapy. He presented therapeutic strategies for RMC-5127, which selectively blocks the growth signals of cancer cells with KRAS mutations, as well as ASP5834, a novel drug candidate that degrades KRAS mutant proteins. He emphasized the importance of translational research that bridges basic research with clinical applications, as well as international collaborative research.



Professor Park commented, "Recent technological advances are opening up new therapeutic prospects targeting KRAS," and added, "It is significant that basic scientific research can ultimately translate into treatments that extend actual patient survival." Hyejin Choi, Head of Medical Oncology at Yonsei Cancer Hospital, remarked, "This was an opportunity to share the latest research outcomes and therapeutic strategies from a world-renowned cancer drug development researcher," and added, "We will continue to expand international research collaboration to strengthen our competitiveness in cancer treatment research."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing